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Abstract: 
Idiopathic Parkinson’s disease is a progressive neurodegenerative disorder 
clinically manifested by cardinal motor symptoms including tremor at rest, 
bradykinesia and muscle rigidity. Transplantation of dopaminergic neurons 
is an experimental therapy for Parkinson’s disease, however, limited by 
suboptimal integration and low survival of grafts. Pretreatment of donor 
tissue may offer a strategy to improve properties of transplanted 
dopaminergic neurons and thereby clinical outcome. We have previously 
shown that a combination of neurotrophin-4/5 (NT-4/5) and glial cell line-
derived neurotrophic factor (GDNF) demonstrated additive effects on rat 
ventral mesencephalic tissue. The present study investigated the effects of 
NT-4/5 and GDNF as single factors or in combination on dopaminergic 
neurons in organotypic explant cultures of fetal human ventral 
mesencephalon. For that purpose free-floating roller-tube cultures were 
prepared from ventral mesencephali and the equally sized pieces grown for 
one week in presence or absence of neurotrophic factors. Both 
neurotrophic factors increased dopamine content in the culture medium 
and number of tyrosine hydroxylase immunoreactive (ir) neurons, most 
prominently after combined GDNF+NT-4/5 treatment. Culture volumes did 
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not differ between groups, while content of lactate dehydrogenase in the 
culture medium was moderately reduced in all treated groups. In 
conclusion, we identified that a combination of GDNF and NT-4/5 robustly 
promoted differentiation and survival of human fetal ventral mesencephalic 
dopaminergic neurons, an observation with potential promising impact for 
cell replacement approaches in Parkinson's disease. 
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Abstract  
Idiopathic Parkinson’s disease is a progressive neurodegenerative disorder clinically 
manifested by cardinal motor symptoms including tremor at rest, bradykinesia and 
muscle rigidity. Transplantation of dopaminergic neurons is an experimental therapy 
for Parkinson’s disease, however, limited by suboptimal integration and low survival 
of grafts. Pretreatment of donor tissue may offer a strategy to improve properties of 
transplanted dopaminergic neurons and thereby clinical outcome. We have 
previously shown that a combination of neurotrophin-4/5 (NT-4/5) and glial cell line-
derived neurotrophic factor (GDNF) demonstrated additive effects on rat ventral 
mesencephalic tissue. The present study investigated the effects of NT-4/5 and 
GDNF as single factors or in combination on dopaminergic neurons in organotypic 
explant cultures of fetal human ventral mesencephalon. For that purpose free-
floating roller-tube cultures were prepared from ventral mesencephali and the 
equally sized pieces grown for one week in presence or absence of neurotrophic 
factors. Both neurotrophic factors increased dopamine content in the culture 
medium and number of tyrosine hydroxylase immunoreactive (ir) neurons, most 
prominently after combined GDNF+NT-4/5 treatment. Culture volumes did not differ 
between groups, while content of lactate dehydrogenase in the culture medium was 
moderately reduced in all treated groups. In conclusion, we identified that a 
combination of GDNF and NT-4/5 robustly promoted differentiation and survival of 
human fetal ventral mesencephalic dopaminergic neurons, an observation with 
potential promising impact for cell replacement approaches in Parkinson's disease. 
 
Key Words: Parkinson’s disease, Cell transplantation, Ventral mesencephalon, 
Neurotrophic factors, Dopamine 
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3 
Introduction 
Progressive loss of dopaminergic (DAergic) neurons in the substantia nigra pars 
compacta is critically implicated for the motor symptoms observed in patients suffering 
from Parkinson’s disease (PD). While drug therapies provide an effective means to 
substitute for the missing intrastriatal dopamine long-term treatment is often going 
along with severe side-effects. In this context, cell replacement strategies in PD have 
emerged as an experimental therapeutic concept. Thereby, the transplanted cells serve 
as a biological pump releasing dopamine. Human fetal nigral tissue can be 
transplanted safely and it has been shown that grafts survived and re-innervated the 
host striatum of PD patients1-4. This approach, however, is limited by suboptimal 
survival and differentiation of grafted DAergic neurons1. 
Hence, alternative sources of transplantable DAergic neurons have been investigated 
including induced pluripotent stem cells (iPSC) and embryonic stem cells (ESC) but 
also their capacity to re-innervate the diseased striatum in rodents was found to be 
critical5. A number of neurotrophic factors have been described to increase the survival 
and growth of DAergic neurons including the glial cell line-derived neurotrophic factor 
(GDNF) and neurotrophin-4/5 (NT-4/5)6. GDNF belongs to the transforming growth 
factor-β superfamily and mediates its cellular responses by a multicomponent receptor 
complex composed of the RET and GDNF family receptor α (GFR-α). In cultures of 
fetal midbrain, GDNF promotes survival and differentiation of DAergic neurons and 
increase high-affinity dopamine uptake7,8. NT-4/5 is a member of the neurotrophin 
family. Upon TrkB receptor binding NT-4/5 initiates intracellular signaling cascades 
including the Ras-PI3K-Akt and the phospholipase-C gamma 1 pathways9,10. In 
mesencephalic primary cultures, NT-4/5 has been shown to enhance the morphological 
complexity and to stimulate the survival of DAergic neurons11,12. In line with these 
reports, we have shown that GDNF and NT-4/5 administration resulted in a significant 
higher survival rate of rat VM tyrosine hydroxylase immunoreactive (TH-ir) neurons 
grown for one week as free-floating roller-tube (FFRT) cultures and also increased their 
DA release6. 
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4 
Transient storage of donor tissue in FFRT culture offers the possibility of exposing cells 
with growth factors prior to grafting. We and others have previously shown that 
pretreated donor tissue resulted in a better outcome13. Support for growth factor pre-
treatment prior to transplantation is furthermore given by a recent study which 
demonstrated that FGF2-mediated pre-grafting expansion of primary VM precursor 
cells considerably improved dopaminergic cell survival and functional restoration in a 
rat model of PD14. 
To the best of our knowledge so far no studies have been performed analyzing the 
effects of a combined GDNF and NT4/5 administration on VM tissue of human origin. 
Hence, in the present study we aimed at investigating whether treatment with 
combined exposure to GDNF and NT-4/5 improves DAergic neurons survival and 
augments dopamine release as compared to single factor treatment. 
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Methods 
Human tissue 
All experiments were carried out in accordance with the Ethics Committee of the 
Medical Faculty of the University of Bern and the Ethics Committee of the State Bern, 
Switzerland (study No. 181/07). Written consent was given by the women seeking 
abortion. 
 
Tissue culture 
Free-floating roller-tube (FFRT) cultures were prepared from ventral mesencephali 
(VM) derived from aborted human fetuses as described in detail by Spenger and co-
workers15,16. The embryonic age of the specimen was 8 to 9 weeks post-conception for 
analysis of cell numbers and dopamine content and 7 to 10 weeks post-conception for 
Western blot analysis and lactate dehydrogenase (LDH) measurements as determined 
by the method of Evtouchenko and coworkers17. In brief, the ventral mesencephalic 
tissue were dissected out and divided into two equal sized portions corresponding to 
the left and right side and then further divided into equally sized small pieces. Each 
piece was transferred into labeled conical plastic tubes (Falcon) containing 1 ml of 
culture medium and placed in a roller-drum in an incubator for one week16. The cultures 
were grown in medium containing 55% Dulbecco´s modified Eagle medium (DMEM, 
Gibco Reinach, Switzerland), 32,5% Hanks balanced salt solution (HBSS, Gibco), 
1,5% glucose, 10% fetal calf serum (FCS, Gibco No. 013-06290) and 1% 0.01 M 
Hepes (Merck KGaA, Darmstadt, Germany). Antibiotics (Gibco) were present during 
the entire culture period. The culture tubes were randomly assigned to the GDNF (10 
ng/ml; Promega AG, Dübendorf, Switzerland), NT-4/5 (10 ng/ml; Promega), the GDNF 
plus NT-4/5 group and to the control group (n= 4 - 12 cultures per group for each of the 
three independent experiments). The medium was changed every other day. 
Neurotrophic factors were added at day 0 and then at each medium change. Control 
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6 
cultures were grown in medium with no trophic factors added. 
 
Analysis of dopamine content in the culture medium by HPLC  
At the end of the culture period the medium was collected and a dopamine stabilizing 
solution (0.22 mg metabisulfite per 50 µl in 7.5% orthophosphoric acid) was added. 
Dopamine was determined using reversed phase HPLC with electrochemical detection 
as described in detail elsewhere6. Mean dopamine content in control cultures was 24.1 
± 4.4 pg/ml (mean ± SEM). 
 
Immunohistochemistry and morphometric analyses 
Cultures were washed two times with ice cold Hank’s balanced salt solution, pooled and 
fixed in 4 % paraformaldehyde in 0.1M phosphate buffered saline (PBS; pH 7.4) for 45 
min. at room temperature followed by cryoprotection in 20% sucrose in 0.1M PBS 
containing 0.01% NaN3 for 24 hrs. Cultures were sectioned at 20 µm on a freezing 
microtome (Frigocut 2800 N, Reichert-Jung) and mounted on gelatin chrome-alum 
precoated glass slides. Sections were washed in PBS preincubated for 60 min. in PBS 
containing 0.3% Triton X-100 and 10% horse serum and incubated for 48 h at 4°C with 
primary antibodies against rabbit anti-TH (1:1000, Pel Freez Bio, Rogers, AR, USA) 
diluted in PBS containing 0.1% Triton X-100 and 2.5% horse serum. Following washes, 
sections were incubated with biotinylated anti-rabbit antibodies (1:200; Vector, 
Burlingame, California, USA). Bound antibodies were visualized with the avidin-
peroxidase complex method and the metal enhanced 3, 3’-diaminobenzidine-based kit 
(Pierce, Rockford, Illinois, USA). Slides were then washed, dehydrated and covered 
with Eukitt (O. Kindler GmbH, Freiburg, Germany). Quantification of TH-ir neurons was 
performed by bright field microscopy by means of a neuron tracing system using a x20 
objective6. Cell numbers were corrected for double counting according to 
Abercrombie's formula 18 and were normalized as TH-ir cell densities (number of TH-ir 
cells / mm2) and shown as percent of controls. Mean TH-ir cell densities in control 
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7 
cultures were 71.3 ± 8.3 cells / mm2 (mean ± SEM). Culture volumes were assessed by 
computer-assisted image analysis as described elsewhere6. Mean culture volumes in 
control cultures were 0.47 ± 0.07 mm3 (mean ± SEM).  
 
Analysis of lactate dehydrogenase content in the culture medium 
At the end of the culture period the medium was collected and used for Lactate 
dehydrogenase (LDH) level measurements as described in detail earlier6. Values are 
expressed as percent of controls of four independent experiments (n=17 - 20 per 
group).  
 
Western blotting  
Proteins were analyzed by SDS-polyacrylamide minigel electrophoresis as described 
previously6. Briefly, cultures were washed two times with ice cold Hank’s balanced salt 
solution and then pooled for each group. The prepared lysates were subjected to a 
12% SDS-polyacrylamide separating gel and the proteins blotted to a polyvinylidene 
difluoride membrane (BioRad, Basel, Switzerland). After electrophoretic transfer the 
blots were decorated with mouse anti-TH (1:500, Millipore, Billerica, Massachusetts, 
USA) or mouse anti-GFAP (1:500, Millipore) antibodies. Visualization of bound 
antibody was performed using anti-mouse antibody-peroxidase conjugates (1:10000, 
Nordic Immunological Laboratories, USA) and the ECL method (Amersham, Glattbrug, 
Switzerland). For loading control and densitometric analyses membranes were re-
probed with mouse monoclonal alpha tubulin (1:20000, Sigma-Aldrich Chemie GmbH, 
Buchs, Switzerland). Experiments were done in triplicate. 
 
Statistics 
For the statistical analysis a commercially available software package was used 
(GraphPad Prism 6, La Jolla, California, USA). The experimental groups were 
compared using the Kruskal-Wallis nonparametric ANOVA test in combination with the 
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8 
Dunn's multiple comparison post hoc analysis. Differences were considered statistically 
significant at p < 0.05. Values are presented as mean ± SEM. 
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9 
 
Results 
Immunohistochemical analysis of the cultures disclosed higher TH-ir neurons cell 
densities in the GDNF, NT-4/5 and GDNF plus NT-4/5 treated groups (3 fold, 5 fold and 
9 fold after GDNF, NT-4/5 and the combination treatment, respectively) as compared to 
untreated controls (Fig. 1A). Moreover, the combination treatment resulted in increased 
surviving TH-ir cell numbers as compared to all other groups (Fig. 1A). In contrast, 
culture volume did not differ significantly between controls and experimental groups 
with slightly increased volumes found for the GDNF plus NT-4/5 group (by 22%) as 
compared to controls (Fig. 1B). Similar to the outcome seen on cell densities of TH-ir 
neurons, significantly augmented TH protein levels in tissue lysate were observed in 
the growth factor treated groups as compared to controls (Fig. 2A,B). We next 
reasoned whether the release of dopamine might have paralleled these effects on the 
TH-ir neurons. Indeed the levels dopamine in the culture medium were increased in all 
neurotrophic factor treated groups (4.5 fold, 5.5 fold and 6.5 fold after GDNF, NT-4/5 
and the combination treatment, respectively) as compared to controls. Accordingly, the 
treatment with NT-4/5 and GDNF+ NT-4/5 exerted the same increase in dopamine 
release in the culture medium (Fig. 1C). 
Western blot analysis for GFAP did not show increased levels in the neurotrophic factor 
treated cultures as compared to controls (Fig. 2C,D). The level of lactate 
dehydrogenase (LDH), released into the culture medium from dead or degenerating 
cells was lower after growth factor treatment as compared to untreated control cultures 
(100.0 ± 5.2%, 90.5 ± 1.3%, 91.4 ± 0.9%, and 90.2 ± 1.6% for control, GDNF, NT-4/5 
and the combination treatment, respectively). 
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10 
 
Discussion 
In the present work we demonstrate that the combination of NT-4/5 and GDNF has 
an additive effect on TH-ir cell numbers in organotypic explant cultures of fetal 
human ventral mesencephalon. Moreover, we have found that the combined 
treatment is superior to each of the single factors in improving the survival and the 
expression of structural and biochemical functional markers of cultured fetal DAergic 
neurons. Overall these observations substantiate and extend our earlier report on 
VM-FFRT cultures of rat origin6. 
Optimal growth, differentiation, and survival of DAergic neurons during development 
require a concerted action of different neurotrophic factors. In translational settings, 
several studies have addressed whether the neuronal supporting actions of different 
neurotrophic factors including GDNF and neurturin can be exploited to improve the 
efficacy of cell transplantation approaches for PD. Indeed, GDNF has already been 
reported to reduce apoptosis in DAergic neurons19 and to promote DAergic fiber 
growth in fetal nigral grafts20. Application of NT4/5 and GDNF furthermore, protected 
DAergic neurons from toxin-induced cell death21 and GDNF was found to exert anti-
apoptotic effects on the DAergic neurons19,22. These observations suggest that the 
reduction of apoptosis events might be one of the mechanisms involved in the 
higher number of TH-ir neurons in the NT4/5 and GDNF treated samples. Indeed, 
this notion seems to be supported by the lower LDH levels measured after growth 
factor treatment. Notably and conversely to the additive actions observed on TH-ir 
cell densities, however, levels of released LDH did not differ amongst the growth 
factors treated groups. Thus, this outcome does not support the idea that the higher 
TH-ir cell densities are the result of a substantial reduction in cell death; rather these 
findings might be better explained by an enhanced specific maturation and / or 
differentiation of the TH-ir cells sub-population. In agreement with this hypothesis we 
have observed no significant differences in culture volume between groups. 
Moreover, in agreement to our previous study using cultures of rat origin6, GFAP 
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11 
protein levels were not affected by the treatments. Nevertheless, the mechanisms 
underlying the increased TH-ir cell densities were not investigated in the present 
study and we cannot exclude that other neuronal phenotypes were also promoted 
by the treatments. In fact, it has been reported that GDNF and neurotrophins 
stimulate the survival and growth of a wider range of neurons including striatal and 
cortical GABAergic neurons9,23-25.  
From a functional standpoint in the cell transplantation paradigm for PD, the 
capacity to release substantial amount of dopamine is a crucial disease changing 
pattern. We previously demonstrated that BDNF treatment increased the number of 
cultured DAergic neurons and elevated dopamine levels in the culture medium26. 
Moreover, we reported a moderate but beneficial survival promoting effect of 
combined GDNF and BDNF treatment on rat fetal nigral tissue20. In the present 
study, HPLC measurements of dopamine in the culture medium disclosed 
pronounced effects after single factor treatment as compared to controls. 
Interestingly, only a tendency for additivity was detected. Although this outcome 
appears in contrast to the findings of Studer and co-workers, i.e. that TH-ir cell 
numbers correlate with dopamine content in the culture medium27, it should be noted 
that in the mentioned study only cultures not exposed to growth factors were 
investigated. The mechanisms accounting for our observation need to be further 
explored and might involve differences in the degree of DAergic neurons maturation 
induced by NT4/5 and GDNF possibly due to differences in the expression of the 
respective receptors. Importantly to note, even though Mendez and co-workers 
reported a substantial increased fluorodopa uptake in two parkinsonian patients 
receiving grafts exposed to GDNF28 it is clearly necessary to verify the effectiveness 
of the combined NT4/5 and GDNF pre-treatment regimen of human mesencephalic 
tissue in animal models of PD.  
 
Conclusions 
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12 
Recent evidence supports the view that the intrastriatal delivery of dopaminergic 
neurons might develop into a safe and effective therapeutic option for PD29. Although 
the human iPSC-derived DAergic cells hold a considerable potential due to the 
unrestricted availability, high purity and minor ethical concerns, they appear to be less 
effective compared to the fetal-derived neurons. On the other hand the limited 
availability of fetal donor tissue and the generally poor survival of the grafted DAergic 
neurons are still major issues to be solved for successful cell replacement 
interventions29. The present study demonstrates that exposure of human DAergic nigral 
neurons grown as FFRT cultures to a combination of GDNF and NT-4/5 significantly 
improved quality of donor tissue and that this combination is overall superior compared 
to the single factor treatments. Further studies in PD will be needed to verify the 
significance of the pre-engraftment treatment described here. Nevertheless, it can be 
assumed that our findings likely also have impact for cell replacement approaches 
using iPSC- and / or ESC-derived donor cells. 
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Figure legends 
 
Fig. 1. Effects of GDNF (gray bars), NT-4/5 (dark gray bars) and combined 
neurotrophic factor treatment (black bars) on tyrosine hydroxylase (TH) positive cell 
densities (A), culture volume (B) and dopamine content in the culture medium (C). 
Ventral mesencephalic FFRT cultures were grown for one week in absence (control, 
open bars) or presence of neurotrophic factors. Data in the bar graphs are given as a 
percentage of control values and are expressed as mean + SEM. *: p< 0.05 vs 
corresponding control. a: p< 0.05 vs all groups. 
 
Fig. 2. Representative microphotographs TH-ir cells from human ventral 
mesencephalic free-floating roller-tube cultures grown for 7 days without 
(control; A) or with addition of NT-4/5 and GDNF (comb; B). Scale bars: 100µm 
and 50µm (inserts). Representative Western blot analyses for TH (C) and GFAP 
(D) protein levels from human ventral mesencephalic free-floating roller-tube 
cultures grown for 7 days without (control) or with addition of NT-4/5 and GDNF 
(comb). Note that the combined treatment resulted in a significantly increased 
TH signal intensity as compared to the control group (C) whereas no difference 
in GFAP signal intensities between groups was observed (D). Membranes were 
re-probed with α-tubulin as a loading control. *: p< 0.05 vs corresponding 
control. 
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